From the strict perspective of some investors, astute financial management by a company to bolster its share price is a good thing. By this narrow logic, when it comes to the pharmaceutical industry, we should be unconcerned if drug firms’ share prices are boosted not by new discoveries, but by financial maneuvers, such as share buybacks or tax inversion.
https://www.project-syndicate.org/commentary/market-obstacles-to-new-antibiotics-by-jim-o-neill-2016-04
I-BRIDGE's blog (Link Campus University's Research Centre on Global Affairs) - editor, Marco Emanuele - Critical thinking, complexity, international relations (Twitter, @Glob_Eye - Facebook, https://www.facebook.com/marco.emanuele.50)
No comments:
Post a Comment